![](https://cdn.prod.website-files.com/63da4ae4359b4b2bffd2a3b6/6453da50b37b0cf2335f4195_article-hero.jpg)
Related articles
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/645acebd4c26031990557a26_ben-kolde-t9DooibgMEk-unsplash.jpg)
Use Case: Integrating consent data to reduce administrative burden
A top-10 pharmaceutical company was looking to reduce the amount of administrative burden on their clinical trial sites and themselves.
The sponsor sought to find a vendor that could use one eConsent system to manage paper and electronic consent.
Additionally, they sought to use the central eConsent system to populate the clinical trial sites’ IRB and EDC systems, as well as some internal systems.
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/644ffc82232d6018ad2d3c5d_medable-abstract-background-clicnaical-trials-patient-recruitment.jpg)
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/641843f1494f165a3cf5fe92_article-image-placeholder-4.jpg)
What is SaaS, and how are life science companies using it today?
In today's digital age, Software as a Service (SaaS) has emerged as a cornerstone of cloud computing, transforming how businesses and individuals access and utilize software applications.
This cloud-based software deployment model has become increasingly popular due to its accessibility, cost-effectiveness, and scalability. Now, SaaS is making significant inroads in the pharmaceutical and life sciences industries, offering solutions to longstanding challenges and driving innovation.
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/65ce0dc2929e7e1c64007c38_SCOPE%202024.jpg)
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/64482e8f985430a5be0f547f_medable-man-reclining-reading-ipad-article-patient-centricity.jpg)
Evidence generation evolved
The pharmaceutical industry faces a daunting challenge: it takes an average of 12 years and $3 billion to bring a new drug to patients, with the FDA approving an average of 50 new therapies yearly.
This pace is inadequate to address humanity's needs and our own future goal of helping the industry produce ten times the number of treatments it does today.
A significant bottleneck is the lengthy clinical trial process, where Phase 3 studies alone can span three years or more. However, a critical factor compounding these timelines is the difficulty in recruiting sufficient patients for these crucial studies, often adding up to 2 years to the already protracted journey.